Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 29:14:185.
doi: 10.1186/s12936-015-0694-3.

The hyper-reactive malarial splenomegaly: a systematic review of the literature

Stefania Leoni  1   2 , Dora Buonfrate  3 , Andrea Angheben  4 , Federico Gobbi  5 , Zeno Bisoffi  6
Affiliations

The hyper-reactive malarial splenomegaly: a systematic review of the literature

Stefania Leoni et al. Malar J. .

Abstract

Background: The hyper-reactive malarial splenomegaly syndrome (HMS) is a leading cause of massive splenomegaly in malaria-endemic countries. HMS is caused by a chronic antigenic stimulation derived from the malaria parasite. Classic Fakunle's major criteria for case definition are: persistent gross splenomegaly, elevated anti-malarial antibodies, IgM titre >2 SD above the local mean value and favourable response to long-term malaria prophylaxis. The syndrome is fatal if left untreated. The aim of this study is to systematically review the literature about HMS, particularly focussing on case definition, epidemiology and management.

Methods: The search strategy was based on the following database sources: Pubmed, EmBase, Scopus. Search was done in March, 2014 and limited to English, Spanish, Italian, French, and Portuguese.

Results: Papers detected were 149, of which 89 were included. Splenomegaly was variably defined and the criterion of increased IgM was not always respected. The highest prevalence was reported in Papua New Guinea (up to 80%). In different African countries, 31 to 76% of all splenomegalies were caused by HMS. Fatality rate reached 36% in three years. The most frequent anti-malarial treatments administered were weekly chloroquine or daily proguanil from a minimum of one month to lifelong. In non-endemic countries, a few authors opted for a single, short anti-malarial treatment. All treated patients with no further exposure improved. Cases not completely fulfilling Fakunle's criteria and therefore untreated, subsequently evolved into HMS. It seems thus appropriate to treat incomplete or 'early' HMS, too.

Conclusions: For patients not re-exposed to endemic areas, a short course of treatment is sufficient, showing that eradicating the infection is sufficient to cure HMS. Longer (probably lifelong) courses, or intermittent treatments, are required for those who remain exposed. Splenectomy, associated with high mortality, should be strictly limited to cases not responding to medical treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow chart.
Figure 2
Figure 2
African patient with splenomegaly seen at the Centre for Tropical Diseases, Negrar.
See this image and copyright information in PMC

References

    1. Bedu-Addo G, Bates I. Causes of massive tropical splenomegaly in Ghana. Lancet. 2002;360:449–54. doi: 10.1016/S0140-6736(02)09680-0. - DOI - PubMed
    1. Crane G. Recent studies of hyperreactive malarious splenomegaly (tropical splenomegaly syndrome) in Papua New Guinea. P N G Med J. 1986;29:35–40. - PubMed
    1. Fakunle YM, Onyewotu II, Greenwood BM, Mohammed I, Holborow EJ. Cryoglobulinaemia and circulating immune complexes in tropical splenomegaly syndrome. Clin Exp Immunol. 1978;31:55–8. - PMC - PubMed
    1. Ziegler JL. Cryoglobulinaemia in tropical splenomegaly syndrome. Clin Exp Immunol. 1973;15:65–78. - PMC - PubMed
    1. Wells JV. Serum immunoglobulin levels in tropical splenomegaly syndrome in New Guinea. Clin Exp Immunol. 1968;3:943–51. - PMC - PubMed

Publication types